What is PLEX in Oncology?
PLEX (plasma exchange or plasmapheresis) is a therapeutic procedure that mechanically removes circulating antibodies, proteins, and pathogenic substances from blood plasma by extracorporeal separation, primarily used in oncology for treating paraneoplastic neurological syndromes, hyperviscosity syndrome in hematologic malignancies, and severe immune-related adverse events from cancer immunotherapy. 1, 2, 3
Mechanism and Technical Aspects
PLEX involves extracorporeal separation of plasma from cellular blood components using membrane filtration or centrifugation 2. Blood is reconstituted with albumin, fresh-frozen plasma, or crystalloid before reinfusion 2. The procedure nonselectively removes large molecules including:
- Pathogenic antibodies
- Inflammatory cytokines and chemokines
- Immune checkpoint inhibitors
- Paraproteins causing hyperviscosity
Standard dosing consists of 5-10 sessions performed every other day, exchanging approximately twice the blood volume per session 1, 2.
Primary Oncology Indications
Paraneoplastic Neurological Syndromes
PLEX is particularly effective for autoimmune encephalitis associated with cancer, especially when corticosteroids are contraindicated or ineffective 1. The 2021 autoimmune encephalitis guidelines recommend:
- Consider PLEX first in patients with high thromboembolic risk (including known or suspected cancer), severe hyponatremia, or associated brain/spinal demyelination 1
- Use IVIG first in agitated patients or those with bleeding disorders 1
- For severe presentations (NMDAR-antibody encephalitis, refractory status epilepticus, severe dysautonomia), consider combination therapy with steroids/PLEX from the beginning rather than sequentially 1
Hematologic Malignancies
Multiple Myeloma:
- Plasmapheresis should be used as adjunctive therapy for symptomatic hyperviscosity 4, 5
- Institutions vary in using plasmapheresis for adjunctive treatment of renal dysfunction in myeloma cast nephropathy 4, 5, 3
Immune-Related Adverse Events from Checkpoint Inhibitors
PLEX shows promise for severe, steroid-refractory immune-related adverse events (irAEs) from checkpoint inhibitors, though evidence remains limited 3, 6. Potential mechanisms include:
- Accelerating clearance of the checkpoint inhibitor itself
- Removing pathogenic antibodies and inflammatory cytokines
- Attenuating ongoing irAEs and preventing delayed complications 6
Timing appears critical—earlier utilization for life-threatening irAEs may yield more favorable outcomes 6. PLEX has been successfully used for checkpoint inhibitor-induced myositis, resulting in rapid improvement even when other immunosuppressants failed 7.
Important Caveats and Contraindications
Major Limitations:
- Increased bleeding risk due to removal of coagulation factors 1
- Volume shifts problematic in dysautonomic patients 1
- Central line placement risks including line-related thrombosis and infection 1, 8
- Less suitable for agitated patients due to procedural requirements 1
- Hemodynamic instability, electrolyte imbalances 8
Critical Timing Considerations:
When using PLEX with immunotherapy:
- With intravenous cyclophosphamide: Give cyclophosphamide AFTER plasma exchange session 8
- With rituximab: Hold plasma exchange for 48-72 hours AFTER rituximab infusion to avoid removing the therapeutic antibody 8
Not Monotherapy:
PLEX should never be used alone—it must be combined with other immunomodulatory therapies 2. In cardiac transplant antibody-mediated rejection studies, PLEX was always combined with corticosteroids and adjustment of baseline immunosuppression 2.
Evidence Quality
The evidence supporting PLEX in oncology comes primarily from:
- Small retrospective studies and case series 1, 2
- Observational data 3
- No large prospective randomized trials exist for most oncology indications 3
Despite limited high-quality evidence, PLEX remains standard therapy for specific conditions like hyperviscosity syndrome and paraneoplastic neurological syndromes based on consistent clinical experience and biological plausibility 2, 9, 3.